placeholder

Daniel D. Von Hoff., M.D., FACP

Distinguished Professor,
Translational Genomics Research Institute

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ and Senior Consultant of Clinical Investigation at the City of Hope.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many FDA approved agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib and others.

 

Dr. Von Hoff has published more than 741 papers, 143 book chapters and over 1186 abstracts. Dr. Von Hoff received the  2010  David  A.  Karnofsky  Memorial  Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care and most recently the AACR Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.  Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics.